API reference
Relugolix
- CAS number
- 737789-87-6
- Molecular formula
- C29H27F2N7O5S
- Molecular weight
- 623.6 g/mol
About this molecule
Relugolix is an orally available, non-peptide gonadotropin-releasing hormone (GnRH or luteinizing hormone-releasing hormone (LHRH)) antagonist, with potential antineoplastic activity. Relugolix competitively binds to and blocks the GnRH receptor in the anterior pituitary gland, which both prevents GnRH binding to the GnRH receptor and inhibits the secretion and release of both luteinizing hormone (LH) and follicle stimulating hormone (FSH). In males, the inhibition of LH secretion prevents the release of testosterone from Leydig cells in the testes. Since testosterone is required to sustain prostate growth, reducing testosterone levels may inhibit hormone-dependent prostate cancer cell proliferation.
Source: NCI Thesaurus (NCIt), via PubChem.
Identifiers
- IUPAC name
- 1-[4-[1-[(2,6-difluorophenyl)methyl]-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxothieno[2,3-d]pyrimidin-6-yl]phenyl]-3-methoxyurea
- InChIKey
- AOMXMOCNKJTRQP-UHFFFAOYSA-N
- SMILES
- CN(C)CC1=C(SC2=C1C(=O)N(C(=O)N2CC3=C(C=CC=C3F)F)C4=NN=C(C=C4)OC)C5=CC=C(C=C5)NC(=O)NOC
- PubChem CID
- 10348973
Also known as
Relugolix · TAK-385 · Orgovyx · TAK 385 · TAK385 · MYFEMBREE COMPONENT RELUGOLIX · relugolixum · Orgovyx (TN)
Chemical data on this page is drawn from PubChem (National Library of Medicine) and is provided for identification only. Hanpars does not hold stock of every substance listed; availability, grade, documentation and regulatory status are confirmed per enquiry.
Tell us the grade, the quantity and the market.
Send the molecule or ingredient, the specification and the destination. We reply from Tehran with the questions, the documents and the next step.